Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes

Citation:

Oikonomou EK, Suchard MA, McGuire DK, et al. Diabetes Care. 2022 Apr 1;45(4):965-974. PMID: 35120199; PMCID: PMC9016734.